METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENT
AssigneeSana Biotechnology, Inc.
InventorSonja Schrepfer
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions for administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of cells engineered to express an exogenous CD47 polypeptide.
Claims74
A method comprising administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of cells engineered to express an exogenous CD47 polypeptide.
A method comprising administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of T cells engineered to express an exogenous CD47 polypeptide.
A method comprising administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of T cells (i) engineered to express an exogenous CD47 polypeptide and at least one chimeric antigen receptor (CAR) and (ii) having reduced expression of MHC class I HLA molecules, MHC class II HLA molecules, T cell receptor (TCR) alpha, and/or TCR beta.
A method comprising administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of T cells having reduced expression of MHC class I HLA molecules, MHC class II HLA molecules, and TCR alpha and engineered to express an exogenous CD47 polypeptide and a CD19 chimeric antigen receptor (CAR).
A method comprising administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of pancreatic islet cells engineered to express an exogenous CD47 polypeptide.
A method comprising administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of pancreatic islet cells (i) engineered to express an exogenous CD47 polypeptide and (ii) having reduced expression of MHC class I HLA and/or MHC class II HLA molecules.
A method comprising administering to a subject in need thereof a CD47-SIRPα blockade agent, wherein the subject was previously administered a population of pancreatic islet cells (i) engineered to express exogenous CD47, CD46, and CD59 polypeptides and (ii) having reduced expression of MHC class I HLA and/or MHC class II HLA molecules.
A method of reducing a population of cells engineered to express an exogenous CD47 polypeptide in a subject comprising:
- (a) administering to the subject a first dose of a CD47-SIRPα blockade agent;
- (b) determining a first outcome of the first dose of the CD47-SIRPα blockade agent administered in (a);
- (c) optionally administering a second dose of the CD47-SIRPα blockade agent based on the first outcome in (b);
- and
- (d) optionally determining a second outcome of the second dose of the CD47-SIRPα blockade agent administered in (c).
A method comprising:
- (a) quantifying a population of cells engineered to express an exogenous CD47 polypeptide in a subject;
- (b) determining a first dose of a CD47-SIRPα blockade agent that is effective in reducing the population of cells by at least 20%;
- and
- (c) administering the first dose of the CD47-SIRPα blockade agent to the subject.
Dependencies are inferred from the claim text.